<div id="readability-page-1">02:13 PM EST, 11/20/2025 (MT Newswires) -- Revelation Biosciences ( REVB ) said Thursday it is on track to hold a meeting with the US Food and Drug Administration later this year following the submission and acceptance of its end-of-phase 1 meeting package to the regulator.The meeting will establish agency feedback and input into the clinical development and regulatory approval pathway for Gemini as a treatment for acute kidney injury, the company said. MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.</div>

REVB

2025 年 11 月 20 日东部标准时间下午 2:13（MT Newswires）-- Revelation Biosciences（REVB）周四表示，计划在今年晚些时候与美国食品药品监督管理局（FDA）举行会议，此次会议是在向监管机构提交并接受其一期结束会议材料后进行的。该会议将确定机构对 Gemini 作为急性肾损伤治疗方案的临床开发和监管批准路径的反馈和意见，公司表示。MT Newswires 不提供投资建议。未经授权的复制是严格禁止的

Revelation 表示计划在今年晚些时候与 FDA 会面